Insperity, Inc. (NYSE: NSP) reported a fourth‑quarter 2025 net loss of $33 million, translating to a GAAP diluted earnings per share of $(0.88). Adjusted earnings per share for the quarter were $(0.60). Revenue rose 3% to $1.668 billion, while gross profit fell 21% to $172 million as benefits costs climbed sharply, driven by higher inpatient, outpatient, and pharmacy claims. The company’s average number of worksite employees paid per month increased 1% to 312,377 in Q4, reflecting modest client growth amid a challenging macro environment.
Insperity’s full‑year 2025 results showed revenue of $6.812 billion, up 4% from the prior year, and a net loss of $7 million, with diluted EPS of $(0.19). Adjusted full‑year EPS was $1.03, a figure that underscores the company’s ongoing margin compression when compared to the GAAP loss. The company’s gross profit margin contracted to 10.2% from 12.3% in 2024, largely due to the same benefits‑cost pressure that weighed on the quarter.
The company’s worksite employee count averaged 310,089 for the year, a 1% increase from 309,000 in 2024, indicating steady client acquisition despite slower hiring activity in the small‑ and medium‑sized business segment. The modest growth in employee count, coupled with rising benefits costs, explains the decline in gross profit margin and the net loss for the year.
Insperity cited several factors behind the margin squeeze. Elevated benefits costs—reported as $60 per worksite employee per month—driven by higher claims, eroded profitability. Management highlighted pricing actions taken in January 2026, a new UnitedHealthcare contract that reduced pooling levels, and the rollout of its HRScale partnership with Workday as key initiatives aimed at restoring margin. These actions are intended to offset the cost inflation and improve pricing power in the PEO market.
For 2026, Insperity guided for full‑year adjusted EPS of $1.69 to $2.72, a midpoint of $2.21 that falls short of the analyst consensus of $2.44. Adjusted EBITDA guidance of $170 million to $230 million, with a midpoint of $200 million, also trails the consensus estimate of $202 million. The guidance reflects management’s cautious outlook amid ongoing benefits‑cost pressure and macroeconomic uncertainty, while still signaling confidence in a rebound once pricing and cost‑control measures mature.
Chairman and CEO Paul J. Sarvadi said, “We accomplished the key objective of our year‑end transition with a step‑up in gross profit margin, which we believe positions the company for a significant recovery in profitability this year.” He added, “As we enter 2026, we plan to continue emphasizing margin and profit recovery while regaining our growth momentum through HR360 sales, retention initiatives, and the roll‑out of HRScale.” Sarvadi also noted that 2025 was “exceptionally challenging” due to macro headwinds and rising health‑plan costs, but that the company has taken “significant steps” to address these issues.
Investors reacted negatively to the earnings miss and cautious 2026 guidance. The company’s GAAP net loss and adjusted EPS fell short of consensus estimates of $-0.49 and $-0.47, respectively, while revenue of $1.668 billion missed the $1.68 billion estimate by roughly $10 million. The market’s response reflects concerns that the company’s margin recovery will take longer than expected and that benefits‑cost inflation may continue to erode profitability.
Insperity’s results underscore a broader industry trend of margin compression driven by rising healthcare costs and weak client hiring. The company’s strategic focus on pricing actions, contract renegotiations, and the HRScale partnership represents a concerted effort to regain pricing power and diversify revenue streams. The announced workforce realignment—eliminating about 4% of non‑sales roles with a one‑time $9 million charge in Q1 2026—signals a commitment to operating‑expense efficiency. Together, these initiatives aim to stabilize margins and position Insperity for a stronger 2026, though the company remains exposed to macroeconomic headwinds and benefits‑cost volatility.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.